• Corpus ID: 23736856

Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.

@article{Walton1996PreclinicalPO,
  title={Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.},
  author={Michael I. Walton and William Gibson and G. Wynne Aherne and N. Lawrence and Trevor C. Stephens and M N Smith and Ann L. Jackman},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1996},
  volume={277 2},
  pages={
          909-16
        }
}
CB30900 is a novel, potent thymidylate synthase inhibitor which can not be polyglutamated and may be active in cancers expressing low or defective folylpolyglutamate synthetase. Pharmacokinetics were studied in mouse tumors and tissues after bolus or infusion protocols. Elimination was triphasic after 100 mg kg-1 i.v. (T 1/2 alpha, 2.8 min; T 1/2 beta, 19.1 min and T 1/2 gamma, 4.1 hr). Peak concentrations were 716 microM; clearance, 1.19 ml g-1 hr-1; and area under the curve (AUC 0-2 hr), 131… 
Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.
TLDR
The results suggest that antitumor activity is dependent on attaining adequate drug concentrations to affect dTTP pools as well as on the duration of effective drug levels.
Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
TLDR
Although it has not been possible to measure individual polyglutamated forms of ZD1694, the radioimmunoassay provides a convenient means of assessing total drug levels in tissues and is currently the only method suitable for measuring the extent of drug retention in normal tissue and tumour biopsies obtained from patients treated with ZD 1694.
In Vivo Antitumor Efficacy of CW252053, A Folate-based Thymidylate Synthase Inhibitor
TLDR
A higher dose of CW252053 (120 mg/kg) elicited both a 100% cure rate and a 100%" survival rate at the termination of the study, confirming that this compound has very potentin vivo antitumor activity against tumor growth.